share_log

Needham Reiterates Buy on Heron Therapeutics, Maintains $5 Price Target

Benzinga ·  Apr 11 06:02

Needham analyst Serge Belanger reiterates Heron Therapeutics (NASDAQ:HRTX) with a Buy and maintains $5 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment